Watch XENE. Know when insiders buy.
One email the day a filing lands. Free.
XENE
Xenon Pharmaceuticals Inc.
35.95
−0.32 −0.88%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
54
WATCH · insiders 85, shorts 23
Insiders, 90 days
+$1.3M
net buying · 2 buys, 2 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
1 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $3.5BP/E —DIV YIELD —FCF YIELD -9.72%REV TTM —NET INCOME −$409.2MNET CASH $93M52W 33.49 – 70.96NEXT EARNINGS Nov 2SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$123.2M | −$110.7M | — | -1.11 | −$95.4M | $275K | −$95.7M | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$112.3M | −$102.3M | — | -1.17 | −$88.9M | $133K | −$89M | Aug 6 |
| Q4 2025 · Dec 31derived | — | — | — | −$109.8M | −$105.3M | — | -1.31 | −$81.5M | $318K | −$81.8M | Feb 26 |
| Q3 2025 · Sep 30 | — | — | — | −$96.3M | −$90.9M | — | -1.15 | −$71.8M | $281K | −$72M | Nov 3 |
| Q2 2025 · Jun 30 | — | — | — | −$94.2M | −$84.7M | — | -1.07 | −$64.2M | $157K | −$64.4M | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$72.7M | −$65M | — | -0.83 | −$61.7M | $43K | −$61.7M | Aug 6 |
| Q4 2024 · Dec 31derived | — | — | — | −$77.5M | −$65.7M | — | -0.84 | −$54.4M | $783K | −$55.2M | Feb 26 |
| Q3 2024 · Sep 30 | — | — | — | −$73.7M | −$62.8M | — | -0.81 | −$49.7M | $590K | −$50.3M | Nov 3 |
| Q2 2024 · Jun 30 | — | — | — | −$69.1M | −$57.9M | — | -0.75 | −$31.2M | $1.5M | −$32.7M | Nov 3 |
| Q1 2024 · Mar 31 | — | — | — | −$59M | −$47.9M | — | -0.62 | −$46.2M | $188K | −$46.4M | Nov 3 |
| Q4 2023 · Dec 31derived | — | — | — | −$53.7M | −$44.7M | — | -0.64 | −$35.4M | $78K | −$35.5M | Feb 26 |
| Q3 2023 · Sep 30 | — | — | — | −$55.7M | −$48.5M | — | -0.73 | −$48.1M | $1.2M | −$49.3M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$373.1M | −$345.9M | — | -4.36 | −$279.1M | $799K | −$279.9M | — | — |
| FY2024 · to Dec 31 | — | — | −$279.3M | −$234.3M | — | -3.01 | −$181.4M | $3.1M | −$184.5M | — | — |
| FY2023 · to Dec 31 | — | — | −$214.1M | −$182.4M | — | -2.73 | −$151.1M | $5.6M | −$156.7M | — | — |
| FY2022 · to Dec 31 | — | — | −$129.1M | −$125.4M | — | -2.06 | −$101M | $2.9M | −$103.9M | — | — |
| FY2021 · to Dec 31 | — | — | −$79M | −$78.9M | — | -1.77 | −$69.5M | $2M | −$71.6M | — | — |
| FY2020 · to Dec 31 | — | — | −$31.3M | −$28.8M | — | -0.81 | −$48.1M | $2.6M | −$50.8M | — | — |
Every number comes from Xenon Pharmaceuticals Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.